Market Overview

BTIG Sees Limited Upside For Globus Medical, Downgrades To Neutral

Share:
Related
56 Biggest Movers From Yesterday
45 Stocks Moving In Wednesday's Mid-Day Session
Device makers in the green after BSX and EW settle patent fights (Seeking Alpha)

Globus Medical Inc (NYSE: GMED) is up 64 percent year-over-year, but it may be exhausting its potential.

The Rating

BTIG analyst Ryan Zimmerman downgraded Globus Medical to Neutral.

The Thesis

Globus Medical is seen to have ridden intensified investor interest in robotics, which compounded strong fundamentals, a positive year in core spine sales, and a good first quarter for robotics commercialization.

BTIG doesn’t necessarily expect the firm to take a turn for the worse.

“We are not saying 1Q18 will miss with our downgrade today either as we believe there may still be early pent-up demand for ExcelsiusGPS in 1Q,” Zimmerman wrote in a Monday note. “In fact, we believe GMED could beat expectations for the quarter.”

He just doesn’t see much upside — perhaps “a dollar or two” — considering overextended valuation relative to the group and the tailwind of robotics growth already baked into the price.

Price Action

Globus Medical fell more than 1 percent on the downgrade, and at time of publication was trading around $50.11.

Related Links:

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

8 Biotech Stocks With Clinical Trial Outcomes In April

Latest Ratings for GMED

DateFirmActionFromTo
Jan 2019Morgan StanleyDowngradesOverweightEqual-Weight
Dec 2018Credit SuisseInitiates Coverage OnOutperform
Dec 2018Credit SuisseInitiates Coverage OnOutperform

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: btig Ryan ZimmermanAnalyst Color Downgrades Analyst Ratings

 

Related Articles (GMED)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
FOLDCitigroupUpgrades0.0
EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
ARMKBerenbergUpgrades0.0
PENNNomuraUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

DA Davidson Says Its Dropbox Estimates Could Be Conservative: 'We Believe Shares Should Outperform'

Buyer Beware: 5 ETNs To Play The Return Of Market Volatility